Abstract 73P
Background
The number of typical and atypical (defined as mitoses with any morphological appearance other than the typical forms) mitotic figures (MFs) and a high atypical-to-typical mitosis ratio are strongly associated with tumour aggressivity, survival rates, and a predictor of poor response to chemotherapy in breast cancer. Manual detection is time consuming, especially on whole slide images (WSIs). An automated approach is therefore necessary to investigate these aspects on a larger scale. We demonstrate that deep learning can be used to automate this detection, improving on the performance of pathologists.
Methods
All MFs in the mammary carcinoma dataset (21 hematoxylin and eosin (H&E)-stained WSIs with ∼14 000 MFs and ∼36 000 hard negatives) were labelled as typical or atypical. These slides (originally scanned on a Leica scanner) were then rescanned on six other scanners (2x Hammamatsu, 2x 3DHISTECH, Philips, Olympus), and the annotations were registered. This gave a large, multi-scanner dataset, which was used to train a YOLOv6 deep learning object detection model. For testing, all MFs in the (human) TUPAC16 and MIDOG21 datasets were labelled by two pathologists as either typical or atypical. In cases of disagreement, a third reader gave a consensus. We used the alternative version of the TUPAC16 dataset provided by the same authors as the MIDOG21 dataset to reduce potential label bias. We then ran our model on these images and compared the mean average precision (mAP) vs the consensus to the mAPs of the two individual pathologists vs the consensus.
Results
The mAP of our model (0.80) was higher than the average mAP of the two pathologists (0.75, p<0.05), showing that the model can successfully automate the process of MF detection. There was considerable disagreement in the labelling by the two pathologists (14% of cases). By automating the process we reduce this variability, meaning we can more consistently predict clinical outcomes (e.g. survival rates) from our results.
Conclusions
The numbers of both typical and atypical MFs are indicators of patient survival and response to treatment. We have demonstrated an automated deep learning model that can accurately detect these figures and could thus be used for patient survival prediction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Tribun.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Anti-malarial drug quinacrine: A potential molecule for repurposing in targeting human non-small cell lung cancer cells (NSCLC)
Presenter: ANGSHUMAN SARKAR
Session: Cocktail & Poster Display session
Resources:
Abstract
63P - Role of EGFR-targeted therapy in the treatment of advanced and metastatic cervical cancers
Presenter: Abhishek Krishna
Session: Cocktail & Poster Display session
Resources:
Abstract
64P - Isothermal chemical KRAS denaturation assay for monitoring stability and inhibitors interactions
Presenter: Randa Mahran
Session: Cocktail & Poster Display session
Resources:
Abstract
65P - Influence of efflux and uptake transporters on the pharmacokinetics of the SYK inhibitors entospletinib and lanraplenib
Presenter: Nancy Loos
Session: Cocktail & Poster Display session
Resources:
Abstract
66P - Targeting allosteric sites on PDK-1 and PLK-1 with bioactive compounds from <italic>Daucus carota</italic> as a potential therapy for triple-negative breast cancer
Presenter: Kayode Raheem
Session: Cocktail & Poster Display session
Resources:
Abstract
67P - Molecular testing and treatment of patients with advanced solid tumors harboring an NTRK gene fusion: Interim results of the REALTRK registry
Presenter: Corinne Vannier
Session: Cocktail & Poster Display session
Resources:
Abstract
68P - Investigating CDK4/6 palbociclib resistance mechanisms in MCF7 breast cancer cell line
Presenter: Heloise Beutier
Session: Cocktail & Poster Display session
Resources:
Abstract
69P - Osimertinib is selective against NSCLC cells and modulates the multidrug-resistant phenotype in patient-derived cell cultures and co-cultures of NSCLC cells and fibroblasts
Presenter: Sofija Jovanović Stojanov
Session: Cocktail & Poster Display session
Resources:
Abstract
71P - Molecular Tumor Board at the European Institute of Oncology: An early Italian precision oncology experience
Presenter: Edoardo Crimini
Session: Cocktail & Poster Display session
Resources:
Abstract
72P - MDM alterations in patients with advanced or metastatic cancers
Presenter: Iwona Lugowska
Session: Cocktail & Poster Display session
Resources:
Abstract